Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
Go back to Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting| (NASDAQ: RZLT) | Delayed: 4.18 +0.17 (4.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.01 | 52 Week High | $ | |||
| Open | $4.05 | 52 Week Low | $ | |||
| Day High | $4.23 | P/E | N/A | |||
| Day Low | $3.82 | EPS | $ | |||
| Volume | 1,469,707 | |||||



